search
Back to results

Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs

Primary Purpose

Epilepsy Intractable

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
SPEAC System
Sponsored by
Brain Sentinel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Epilepsy Intractable

Eligibility Criteria

22 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject is a veteran with a reported history of motor seizures (epileptic, non-epileptic or unknown) with upper extremity motor involvement, presenting with questionable spell characterization.
  2. Subjects suspected of experiencing one or more spells per month.
  3. Subjects has failed at least 3 anti-epileptic drugs (single or combination).
  4. Male or Female between the ages 22 to 99.
  5. If female and of childbearing potential, subject must agree to not become pregnant during the trial.
  6. Can understand and sign written informed consent or will have a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments.
  7. Subject or Primary Caregiver must be competent to follow all study procedures.
  8. Subject must be willing to use the Seizure Monitoring and Alerting System for a prolonged period (up to five months), for a minimum of 30 hours/ week.

Exclusion Criteria:

  1. The subject cannot be pregnant, or nursing.
  2. The subject cannot be sensitive or allergic to adhesives or tapes.
  3. The subject may not be enrolled in another Clinical Trial.
  4. The subject is homeless or in a home without a power supply.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Treatment Group

    Standard of Care

    Arm Description

    SPEAC System

    Outcomes

    Primary Outcome Measures

    Diagnostic Impact Form Questionnaire
    The physician will complete this questionnaire after each 30 days of device use to determine if information acquired will change the physician's assessment of the patient's seizures and their treatment plan.

    Secondary Outcome Measures

    Personal Impact of Epilepsy Scale (PIES) Survey
    The PIES survey creates a composite score that can be used to assess the quality of life of patients with epilepsy, as well as sub-scales for assessing the quality of life in specific areas of life with epilepsy.
    VR-12 Survey
    This measure has been used in cost-effectiveness analyses and can be used to calculate quality adjusted life years (QALY).
    Personal Impact of Epilepsy Scale (PIES) Survey
    The PIES survey creates a composite score that can be used to assess the quality of life of patients with epilepsy, as well as sub-scales for assessing the quality of life in specific areas of life with epilepsy.
    VR-12 Survey
    This measure has been used in cost-effectiveness analyses and can be used to calculate quality adjusted life years (QALY).
    VA Administrative Data
    Healthcare utilization, medication, and cost data will be collected to determine VA administrative data will be used to evaluate health outcomes.
    VA Administrative Data
    VA administrative data will be used to evaluate health outcomes.

    Full Information

    First Posted
    August 2, 2018
    Last Updated
    July 8, 2019
    Sponsor
    Brain Sentinel
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03741192
    Brief Title
    Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs
    Official Title
    Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2019
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 2020 (Anticipated)
    Primary Completion Date
    January 2021 (Anticipated)
    Study Completion Date
    January 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Brain Sentinel

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Product Manufactured in and Exported from the U.S.
    Yes
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is an open label, randomized, prospective study of the impact on healthcare utilization of a surface Electromyography (sEMG) based seizure monitoring and alerting system for Veterans with seizures with upper extremity motor involvement, that are refractory to three or more antiepileptic drugs.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Epilepsy Intractable

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Participating physicians will recruit patients meeting the inclusion and exclusion criteria. Upon completion of screening and enrollment procedures study participants will be randomly assigned to one of two groups using a randomized call-in system: treatment or standard of care. Demographics will be obtained for both groups during this initial clinic visit. The treatment group will be prescribed the Brain Sentinel® SPEAC System for use in the home environment. Study Participants in the standard of care group will be given standard care.
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    58 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Treatment Group
    Arm Type
    Experimental
    Arm Description
    SPEAC System
    Arm Title
    Standard of Care
    Arm Type
    No Intervention
    Intervention Type
    Device
    Intervention Name(s)
    SPEAC System
    Other Intervention Name(s)
    Brain Sentinel Monitoring and Alerting System
    Intervention Description
    Surface Electromyography (sEMG) based seizure monitoring and alerting system
    Primary Outcome Measure Information:
    Title
    Diagnostic Impact Form Questionnaire
    Description
    The physician will complete this questionnaire after each 30 days of device use to determine if information acquired will change the physician's assessment of the patient's seizures and their treatment plan.
    Time Frame
    Up to 5 months
    Secondary Outcome Measure Information:
    Title
    Personal Impact of Epilepsy Scale (PIES) Survey
    Description
    The PIES survey creates a composite score that can be used to assess the quality of life of patients with epilepsy, as well as sub-scales for assessing the quality of life in specific areas of life with epilepsy.
    Time Frame
    1 year
    Title
    VR-12 Survey
    Description
    This measure has been used in cost-effectiveness analyses and can be used to calculate quality adjusted life years (QALY).
    Time Frame
    1 year
    Title
    Personal Impact of Epilepsy Scale (PIES) Survey
    Description
    The PIES survey creates a composite score that can be used to assess the quality of life of patients with epilepsy, as well as sub-scales for assessing the quality of life in specific areas of life with epilepsy.
    Time Frame
    5 years
    Title
    VR-12 Survey
    Description
    This measure has been used in cost-effectiveness analyses and can be used to calculate quality adjusted life years (QALY).
    Time Frame
    5 years
    Title
    VA Administrative Data
    Description
    Healthcare utilization, medication, and cost data will be collected to determine VA administrative data will be used to evaluate health outcomes.
    Time Frame
    1 year
    Title
    VA Administrative Data
    Description
    VA administrative data will be used to evaluate health outcomes.
    Time Frame
    5 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    22 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subject is a veteran with a reported history of motor seizures (epileptic, non-epileptic or unknown) with upper extremity motor involvement, presenting with questionable spell characterization. Subjects suspected of experiencing one or more spells per month. Subjects has failed at least 3 anti-epileptic drugs (single or combination). Male or Female between the ages 22 to 99. If female and of childbearing potential, subject must agree to not become pregnant during the trial. Can understand and sign written informed consent or will have a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments. Subject or Primary Caregiver must be competent to follow all study procedures. Subject must be willing to use the Seizure Monitoring and Alerting System for a prolonged period (up to five months), for a minimum of 30 hours/ week. Exclusion Criteria: The subject cannot be pregnant, or nursing. The subject cannot be sensitive or allergic to adhesives or tapes. The subject may not be enrolled in another Clinical Trial. The subject is homeless or in a home without a power supply.

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs

    We'll reach out to this number within 24 hrs